Last reviewed · How we verify
ART 44
ART 44 is an antiretroviral drug used to treat HIV-1 infection.
ART 44 is an antiretroviral drug used to treat HIV-1 infection. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1.
At a glance
| Generic name | ART 44 |
|---|---|
| Sponsor | Laboratoires NEGMA |
| Drug class | Non-nucleoside reverse transcriptase inhibitor |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
ART 44 works by inhibiting the replication of HIV-1 through its action on the viral reverse transcriptase enzyme. This mechanism of action helps to reduce the viral load in the body, thereby slowing the progression of the disease.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV-1
Common side effects
- Nausea
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (PHASE3)
- Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals (PHASE2)
- Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 (PHASE2)
- Neuropsychological and Electrophysiological Effects of Dance Therapy With People With Severe Mental Disorders (NA)
- Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection (PHASE1)
- Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis (PHASE2)
- Assisted Reproductive Technology (ART) Predictors Study
- Chloroquine as a Modulator of T Cell Immune Activation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ART 44 CI brief — competitive landscape report
- ART 44 updates RSS · CI watch RSS
- Laboratoires NEGMA portfolio CI